XOMA Royalty (XOMA) Change in Accured Expenses (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Change in Accured Expenses came in at -$2.6 million in Q1 2026, up 19.51% year-on-year from -$2.2 million in Q1 2025, and up 64.24% quarter-over-quarter from -$7.3 million in Q4 2025.
XOMA Royalty (XOMA) Change in Accured Expenses (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Change in Accured Expenses across 17 years of filings, most recently posting -$2.6 million for Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at -$2.6 million, up 19.51% year-over-year; the trailing twelve-month figure through Mar 2026 was -$10.0 million (down 537.64% YoY), and the FY2025 annual result was -$10.6 million, down 763.14% from the prior year.
- Change in Accured Expenses came in at -$2.6 million for Q1 2026 at XOMA Royalty, up from -$7.3 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $3.1 million in Q1 2023 to a low of -$7.3 million in Q4 2025.
- The 5-year median for Change in Accured Expenses is $31000.0 (2023), against an average of -$606176.5.
- Across the five-year window, Change in Accured Expenses surged 9403.23% in 2024 and sank 3009.52% in 2025, its largest moves.
- XOMA Royalty's Change in Accured Expenses stood at $1.2 million in 2022, then tumbled by 97.52% to $31000.0 in 2023, then soared by 9403.23% to $2.9 million in 2024, then tumbled by 349.46% to -$7.3 million in 2025, then soared by 64.24% to -$2.6 million in 2026.
- The last three Change in Accured Expenses figures came in at -$2.6 million (Q1 2026), -$7.3 million (Q4 2025), and -$2.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 931,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | -2.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.63 Mn |
| Mar 31, 2026 | -2.63 Mn |
| Dec 31, 2025 | -7.35 Mn |
| Dec 31, 2025 | -7.35 Mn |
| Sep 30, 2025 | -2.86 Mn |
| Sep 30, 2025 | -2.86 Mn |
| Jun 30, 2025 | 2.88 Mn |
| Jun 30, 2025 | 2.88 Mn |
| Mar 31, 2025 | -3.27 Mn |
| Mar 31, 2025 | -3.27 Mn |
| Dec 31, 2024 | 2.95 Mn |
| Dec 31, 2024 | 2.95 Mn |
| Sep 30, 2024 | -2.27 Mn |
| Sep 30, 2024 | -2.27 Mn |
| Jun 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 1.03 Mn |
| Mar 31, 2024 | -105,000.00 |
| Mar 31, 2024 | -105,000.00 |
| Dec 31, 2023 | 31,000.00 |
| Dec 31, 2023 | 31,000.00 |